STAAR Surgical
Update in progressSTAA (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryMedical Instruments & Supplies
STAAR Surgical and its subsidiaries design, develop, manufacture, and sell phakic implantable lenses and delivery systems. Its EVO ICL family—EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL—supports refractive surgery to treat myopia, hyperopia, astigmatism, and presbyopia. It serves ophthalmic surgeons, centers, hospitals, government facilities, distributors, and ophthalmologists. Direct sales in the US, Japan, Germany, Spain, Singapore, Canada, and the UK; distributors in other regions. Founded 1982; Lake Forest, California.
Company score
- Sentiment
- 0.18
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.06
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.28
- Governance
- -0.04
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.10
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.14
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGM (NGM)
- LocationUnited States
- CEOMr. Warren Foust
- Founded1982
- Employees921
- Websitewww.staar.com
Identifiers
- ISINUS8523123052
- FIGIBBG000C4QB95
- LEI5299006LRHI7OJ8BY308
- CUSIP852312305
- CIK0000718937